General Hematology
Cohort Study | Incidence and impact of anticoagulation-associated abnormal menstrual bleeding after VTE
27 Jan, 2023 | 12:04h | UTCInvited Commentary: The burden of heavy menstrual bleeding – Blood
Commentary on Twitter
Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism https://t.co/IEftFzyvRl pic.twitter.com/m09sP14inN
— Blood Journal (@BloodJournal) October 26, 2022
Review | Spotlight on vaccine-induced thrombosis and thrombocytopenia (VITT)
26 Jan, 2023 | 12:46h | UTCSpotlight on vaccine-induced thrombosis and thrombocytopenia (VITT) – Blood
RCT | Aspirin noninferior to low-molecular-weight heparin for thromboprophylaxis after a fracture
19 Jan, 2023 | 14:30h | UTCAspirin or Low-Molecular-Weight Heparin for Thromboprophylaxis after a Fracture – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: PREVENT CLOT Supports Aspirin for VTE Prevention in Trauma Fractures – TCTMD
M-A | Optimal timing of perioperative chemical thromboprophylaxis in elective major abdominal surgery
19 Jan, 2023 | 13:52h | UTCOptimal Timing of Perioperative Chemical Thromboprophylaxis in Elective Major Abdominal Surgery: A Systematic Review and Meta-analysis – Annals of Surgery (link to abstract – $ for full-text)
Review | Management of patients with lower-risk myelodysplastic syndromes
19 Jan, 2023 | 13:47h | UTCManagement of patients with lower-risk myelodysplastic syndromes – Blood Cancer Journal
Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score
18 Jan, 2023 | 14:37h | UTCSee calculator: https://vtepredict.com/
Commentary on Twitter
The effect of extended anticoagulant treatment for individual patients with venous thromboembolism: the results from the VTE-PREDICT risk score! #venous #thromboembolism #anticoagulant #bleeding #score#EHJ #cardiotwitter @ESC_Journals @escardio
https://t.co/u3NHWyB9rv pic.twitter.com/ifOFxaXV1I— EHJ Editor-in-Chief (@ehj_ed) January 17, 2023
Retrospective study | Supernumerary sex chromosome aneuploidies are associated with increased risk of VTE
18 Jan, 2023 | 14:22h | UTCAssociation of Supernumerary Sex Chromosome Aneuploidies With Venous Thromboembolism – JAMA (free for a limited period)
ESMO Guideline | Venous thromboembolism in cancer patients
15 Jan, 2023 | 20:21h | UTCVenous thromboembolism in cancer patients: ESMO Clinical Practice Guideline – Annals of Oncology
Related:
Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
Infographic: Cancer-associated venous thromboembolism – Nature Reviews Disease Primers
NCCN Guideline: Cancer-Associated Venous Thromboembolic Disease.
ASH 2021 guidelines for prevention and treatment of venous thromboembolism in patients with cancer
Review: venous and arterial thromboembolism in patients with cancer.
SR | Laser therapy for retinopathy in sickle cell disease
12 Jan, 2023 | 13:02h | UTCLaser therapy for retinopathy in sickle cell disease – Cochrane Library
Summary: Laser therapy for retinopathy in sickle cell disease – Cochrane Library
Review | Antithrombotic therapy after bioprosthetic aortic valve replacement
12 Jan, 2023 | 12:51h | UTC
Review | Platelet transfusion for trauma resuscitation
11 Jan, 2023 | 14:08h | UTCPlatelet Transfusion for Trauma Resuscitation – Current Trauma Reports
Special Issue | American Society of Hematology Education Program (series of open-access review articles)
10 Jan, 2023 | 14:26h | UTCHomepage: American Society of Hematology Education Program – Hematology
Chronic lymphocytic leukemia treatment algorithm 2022
10 Jan, 2023 | 14:05h | UTCChronic lymphocytic leukemia treatment algorithm 2022 – Blood Cancer Journal
Updated Guidance | Acute, periprocedural and long-term antithrombotic therapy in older adults.
16 Dec, 2022 | 13:51h | UTCCommentary: Antithrombotic Therapy in Older Adults: Key Points – American College of Cardiology
RCT | Hypophosphataemia following ferric derisomaltose vs. ferric carboxymaltose in patients with iron deficiency anemia due to IBD.
16 Dec, 2022 | 13:15h | UTC
Major hemorrhage: past, present and future.
13 Dec, 2022 | 14:05h | UTCMajor haemorrhage: past, present and future – Anaesthesia
M-A | Evaluation of direct oral anticoagulant reversal agents in intracranial hemorrhage.
9 Dec, 2022 | 13:17h | UTC
Commentary on Twitter
Meta-analysis finds mostly successful DOAC reversal with 4F-PCC (77%), andexanet alfa (AA)(75%), and idarucizumab (82%) in patients with ICH. 4F-PCC and AA had comparable success in factor Xa inhibitor reversal, mortality, and thromboembolic outcomes. #OA https://t.co/aieJd9h5jo
— JAMA Network Open (@JAMANetworkOpen) November 4, 2022
Preliminary study suggests that Edoxaban is a safe alternative for preventing thromboembolism in pediatric patients with cardiac disease.
9 Dec, 2022 | 13:07h | UTCEdoxaban for Thromboembolism Prevention in Pediatric Patients With Cardiac Disease – Journal of the American College of Cardiology (link to abstract – $ for full-text)
Cohort Study | Cutaneous involvement in catastrophic antiphospholipid syndrome.
8 Dec, 2022 | 12:53h | UTCCutaneous Involvement in Catastrophic Antiphospholipid Syndrome in a Multicenter Cohort of 65 Patients – JAMA Dermatology (free for a limited period)
Commentary on Twitter
In this cohort study, half of patients with catastrophic APS (CAPS) showed cutaneous involvement, with a spectrum of clinical presentations, including distal inflammatory edema. Skin biopsies confirmed diagnosis in all but 1 biopsied patient. https://t.co/lwBL3lyLxT
— JAMA Dermatology (@JAMADerm) December 7, 2022
RCT | Fostamatinib for the treatment of patients with primary immune thrombocytopenia.
7 Dec, 2022 | 14:18h | UTC
RCT | Rivaroxaban prophylaxis in noncirrhotic portal vein thrombosis.
2 Dec, 2022 | 14:24h | UTCRivaroxaban Prophylaxis in Noncirrhotic Portal Vein Thrombosis – NEJM Evidence
Commentary on Twitter
This #RCT examined the use of rivaroxaban to reduce risk of venous thromboembolism (VTE) in pts with non-cirrhotic chronic portal vein thrombosis (PVT). Daily rivaroxaban reduced incidence of VTE and did not increase major bleeding events. https://t.co/CbenUb8ZWz#LiverTwitter pic.twitter.com/bgN1QS171j
— NEJM Evidence (@NEJMEvidence) November 22, 2022
Cohort Study | Trends and risk factors for venous thromboembolism among hospitalized medical patients.
29 Nov, 2022 | 14:04h | UTC
Commentary on Twitter
1.2% of hospitalized patients developed a hospital-associated venous thromboembolism (HA-VTE), slightly increasing from 2013-2016 (1.1-1.6%). 78% happened after discharge; HA-VTE were linked to higher risk of readmission and death. @KPDOR https://t.co/cB8VhY7k7X #OAResearch
— JAMA Network Open (@JAMANetworkOpen) November 21, 2022
RCT | Anticoagulation for 3 months reduces recurrence rates vs. treatment for 6 weeks in patients with isolated distal DVT.
24 Nov, 2022 | 13:34h | UTCNews Release: Extending anti-clotting treatment after distal DVT reduces further clot risk – BMJ Newsroom
SR | Prothrombin complex concentrate in cardiac surgery for the treatment of coagulopathic bleeding.
24 Nov, 2022 | 13:24h | UTC
RCT | Leniolisib for Activated phosphoinositide 3-kinase delta syndrome.
22 Nov, 2022 | 13:12h | UTC